Welcome to our dedicated page for Iridex news (Ticker: IRIX), a resource for investors and traders seeking the latest updates and insights on Iridex stock.
Iridex Corporation (Nasdaq: IRIX) is a medical device company focused on laser-based ophthalmic systems, and its news flow reflects both commercial performance and clinical adoption of its technology. Company announcements frequently highlight revenue trends, probe and system sales for its Cyclo G6® glaucoma product family, and progress toward goals such as positive adjusted EBITDA and cash flow.
Investors following IRIX news can expect detailed quarterly and preliminary financial updates, including information on total revenue, glaucoma and retina product performance, operating expenses, and non‑GAAP metrics. Iridex also issues releases on matters related to its Nasdaq Capital Market listing status, such as notifications of non‑compliance and subsequent confirmation of regained compliance with stockholders’ equity requirements.
Beyond financial results, Iridex regularly reports on clinical and scientific developments involving its MicroPulse® technology and laser platforms. Recent news has covered independent studies on MicroPulse transscleral laser therapy (MicroPulse TLT) for glaucoma retreatment, thermal modeling comparing MicroPulse and continuous‑wave transscleral cyclophotocoagulation using the Cyclo G6 laser and associated probes, and large investigator‑led trials like DAME and DIAMONDS in diabetic macular edema that use the IQ 577® laser and TxCell® Scanning Delivery Device.
Additional items in the IRIX news stream include participation in investor conferences, webcasts, and other corporate presentations. For market participants, clinicians, and researchers, the Iridex news page offers a centralized view of how the company’s glaucoma and retinal treatment technologies are performing commercially and how they are being evaluated in peer‑reviewed studies and large clinical trials.
IRIDEX Corporation (Nasdaq: IRIX) announced preliminary unaudited results for Q4 and the full year 2020. Q4 revenue is projected at $12.2-$12.4 million, an increase from $11.8 million in Q4 2019. Full-year revenue is expected to be $36.2-$36.4 million, down 16% from $43.4 million in 2019. The company sold 13,500 Cyclo G6® probes in Q4, reflecting an 8% increase in U.S. sales. However, sales of Cyclo G6 Glaucoma Laser Systems decreased to 56 units. Cash burn was $0.3 million in Q4 and $1.0 million for the year, signaling effective expense management despite COVID-19 impacts.
IRIDEX Corporation (NASDAQ: IRIX) has announced that its MicroPulse Transscleral Laser Therapy (TLT) is included in the European Glaucoma Society's (EGS) guidelines for glaucoma diagnosis and management. Presented at the EGS Annual Meeting, nine studies highlighted the procedure's safety, effectiveness, and versatility for various types of glaucoma. MicroPulse TLT has treated over 140,000 patients globally and shows promise in significantly reducing intraocular pressure. The increasing recognition and adoption of this non-incisional therapy could positively impact IRIDEX's market position.
IRIDEX Corporation (Nasdaq: IRIX) reported third-quarter financial results for the period ending September 26, 2020. Total revenue was $8.8 million, down 17% year-over-year but up 42% sequentially. The company sold 11,400 Cyclo G6 probes, marking a 6% increase from the prior year and a 44% increase from the previous quarter. However, sales of Cyclo G6 Glaucoma Laser Systems fell to 37 units from 82 a year ago due to COVID-related deferrals. The company ended the quarter with $11.9 million in cash and a reduced net loss of $1.7 million.
IRIDEX Corporation (Nasdaq: IRIX) announced its participation in the Stifel Virtual Healthcare Conference on November 17, 2020, at 4:40 pm ET. David I. Bruce, the CEO, will present, and interested individuals can access the live and archived webcast via the IRIDEX website.
IRIDEX specializes in laser-based medical systems for ophthalmology, notably using MicroPulse technology for treating conditions like glaucoma and diabetic macular edema. Its products are available in over 100 countries.
IRIDEX Corporation (Nasdaq: IRIX) will release its Q3 2020 financial results after trading hours on November 9, 2020. The management team will host a conference call at 2:00 p.m. PT to discuss the results. Interested investors can join via a dedicated phone line or through a live webcast available on the company’s website. IRIDEX is a leading developer of laser-based medical systems for the ophthalmology market, providing innovative treatments for conditions like glaucoma and diabetic macular edema through its proprietary MicroPulse® technology.
IRIDEX Corporation (Nasdaq: IRIX) reported a 40% decline in second-quarter revenues, totaling $6.2 million, compared to $10.4 million in the previous year. Despite a net loss of $2.8 million, the loss was contained due to cost control measures. Cyclo G6 product revenue fell 38.2% year-over-year. However, probe shipments rebounded, exceeding 80% of pre-COVID levels by June. Ending cash balance stood at $11.6 million, bolstered by a $2.5 million PPP loan. The company refrained from providing full-year guidance due to ongoing uncertainties.
IRIDEX Corporation (Nasdaq: IRIX) will announce its second quarter 2020 financial results after trading on August 6, 2020. Management will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET, with dial-in options for domestic (844-707-0665) and international callers (703-326-3030), using conference ID: 6486158. A live and archived webcast will be available on the company’s website. IRIDEX specializes in laser-based medical systems for ophthalmology, utilizing its MicroPulse® technology to address conditions like glaucoma and diabetic macular edema.
Summary not available.